CAS 132810-10-7
:Blonanserin
Description:
Blonanserin is an atypical antipsychotic medication primarily used in the treatment of schizophrenia. It functions as a dopamine D2 receptor antagonist and a serotonin 5-HT2A receptor antagonist, which contributes to its therapeutic effects in managing psychotic symptoms. The chemical structure of Blonanserin includes a piperazine moiety, which is common in many antipsychotic drugs, and it exhibits a unique profile of receptor binding that may lead to a lower incidence of extrapyramidal side effects compared to traditional antipsychotics. Blonanserin is typically administered orally and has been shown to improve both positive and negative symptoms of schizophrenia. Its pharmacokinetics indicate a moderate half-life, allowing for once-daily dosing in clinical practice. As with other antipsychotics, potential side effects may include weight gain, sedation, and metabolic changes, necessitating careful monitoring during treatment. Overall, Blonanserin represents a valuable option in the pharmacological management of schizophrenia, particularly for patients who may not respond adequately to other treatments.
Formula:C23H30FN3
InChI:InChI=1S/C23H30FN3/c1-2-26-13-15-27(16-14-26)23-17-21(18-9-11-19(24)12-10-18)20-7-5-3-4-6-8-22(20)25-23/h9-12,17H,2-8,13-16H2,1H3
InChI key:InChIKey=XVGOZDAJGBALKS-UHFFFAOYSA-N
SMILES:FC1=CC=C(C2=C3C(=NC(=C2)N4CCN(CC)CC4)CCCCCC3)C=C1
Synonyms:- 2-(4-Ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine
- 2-(4-Ethyl-1-piperazinyl)-4-(p-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine
- 2-(4-Ethylpiperazin-1-Yl)-4-(4-Fluorophenyl)-5,6,7,8,9,10-Hexahydrocycloocta[B]Pyridine
- Ad 5423
- Cycloocta(b)pyridine, 2-(4-ethyl-1-piperazinyl)-4-(1-fluorophenyl)-5,6,7,8,9,10-hexahydro-
- Cycloocta(b)pyridine, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro-
- Lonasen
- Blonanserin
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 9 products.
Blonanserin
CAS:Formula:C23H30FN3Purity:>98.0%(HPLC)Color and Shape:White to Almost white powder to crystalMolecular weight:367.51Cycloocta[b]pyridine, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro-
CAS:Formula:C23H30FN3Purity:98.0%Color and Shape:SolidMolecular weight:367.5028Blonanserin
CAS:<p>Blonanserin (AD-5423), approved in Japan (2008), is an atypical antipsychotic with fewer side effects like EPS, sedation, or hypotension.</p>Formula:C23H30FN3Purity:99.85%Color and Shape:SolidMolecular weight:367.5Blonanserin
CAS:Controlled Product<p>Applications A 5-HT2 serotonin receptor and D2 dopamine receptor antagonist, used as an antipsychotic.<br>References Oka, T., et al.: Life Sci., 76, 225 (2004), Singh, A., et al.: Int. Med. J., 12, 175 (2005), Ochi, T., et al.: Bioorg. Med. Chem., Lett., 15, 1055 (2005),<br></p>Formula:C23H30FN3Color and Shape:NeatMolecular weight:367.50Blonanserin
CAS:Controlled Product<p>Blonanserin is a drug for the treatment of congestive heart failure. It is a potent and selective antagonist of 5-HT2A receptors. Blonanserin was shown to increase serum prolactin levels in humans, and has been shown to decrease locomotor activity in rats. The effects on locomotor activity are not due to its effect on dopamine or serotonin levels, but may be caused by its matrix effect on 5-HT2A receptors. The long-term efficacy of blonanserin has been demonstrated by the fact that it can be used as a pharmacological treatment for Parkinson's disease and schizophrenia.</p>Formula:C23H30FN3Purity:Min. 95%Molecular weight:367.5 g/mol
![Cycloocta[b]pyridine, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro-](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA00117R.jpg&w=3840&q=75)
